Clinical Trials
18 trialsNCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT05168748 2022-12-21
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
Novartis
Phase 1 Withdrawn
NCT04807478 2022-08-04
Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
Fresenius Kabi
Withdrawn
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT01101581 2021-08-18
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Gilead Sciences
Phase 1/2 Withdrawn
NCT02487459 2020-10-05
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT03888534 2020-09-28
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Takeda
Phase 1 Withdrawn
NCT03628053 2020-07-09
OBERON
Novartis
Phase 3 Withdrawn
NCT03187691 2019-03-08
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Matinas BioPharma Nanotechnologies, Inc.
Phase 2 Withdrawn
NCT03515785 2018-12-14
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Incyte Corporation
Withdrawn
NCT02269579 2018-03-14
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT03141398 2017-07-26
CGMs
Hamad Medical Corporation
Withdrawn
NCT02973191 2017-04-10
ORBIT
Celgene
Phase 1/2 Withdrawn
NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
NCT02150928 2015-05-13
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn